Roche Holding Ltd · SIX:RO
Roche — ZKB Swiss Equity Conference 2022
32 slides from Roche's conference presentation, Nov 3, 2022
Slide 1: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 2: 2022 – Innovation as driver
2022 – Innovation as driver Bruno Eschli | Head of IR Roche ZKB Swiss Equity Conference, Zürich, 3 November 2022
Slide 3: YTD Performance update, pipelines, innovation, outlook
YTD Performance update Pharma pipeline Diagnostics pipeline Drive for innovation Outlook
Slide 4: YTD Sep 2022: Portfolio rejuvenation ongoing
YTD Sep 2022: Portfolio rejuvenation ongoing CHFm +2% at CER -383 + 2'397 -612 +217 -1,460 + 621 -427 46'684 47'037 YTD Sep Dia Dia Pharma Ronapreve Actemra AHR Fx YTD Sep base COVID-19 underlying sales sales erosion1 2021 business sales business 2022 YTD Sep 2022 values in reported CHFm, variances
Slide 5: YTD Sep 2022: Solid underlying sales growth in both divisions
YTD Sep 2022: Solid underlying sales growth in both divisions Pharma Diagnostics Quarterly sales evolution 2021-2022 Quarterly sales evolution 2021-2022 % CER % CER +55% +55% +48% +45% +55% +45% +35% +35% +31% +24% +25% +25% +17% +18% +15% +14% +15% +9% +7% +4% +5% +6% +6% +3% +5% +2% +5% +11% +10%
Slide 6: Pharma portfolio diversification progressing
Pharma portfolio diversification progressing YTD 2022 absolute growth of products at CER Diversification of Roche business YTD Sep 2017 YTD Sep 2022 CHF 39.4bn CHF 47.0bn Ocrevus 17% Hemlibra 28% Evrysdi 101% AHR Phesgo 150% Vabysmo n/a Tecentriq 10% Alecensa 16% AHR Kadcyla 11% Perjeta 5% Xolair 10
Slide 7: YTD Performance update, pipelines, innovation, outlook
YTD Performance update Pharma pipeline Diagnostics pipeline Drive for innovation Outlook
Slide 8: 2022/23: Upcoming Pharma newsflow
2022/23: Upcoming Pharma newsflow 2022 2023 Vabysmo in RVO Tiragolumab + Tecentriq in 1L PDL1+ NSCLC Susvimo in DME Tiragolumab + Tecentriq in 1L Esophageal Susvimo in DR Tecentriq in adjuvant HCC Venclexta in R/R MM (t11;14) Tecentriq in adjuvant SCCHN Gantenerumab in Alzheimer’s disease Tecentriq
Slide 9: Ophthalmology franchise: Excellent Vabysmo launch
Ophthalmology franchise: Excellent Vabysmo launch More than 165k vials shipped in the US in the first 7 months Q3 update CHFm Vabysmo 200 • US: Strong uptake with switches primarily from aflibercept and first naïve patient starts 150 • US: Permanent J-code received on October 1st 100 • EU: Approval
Slide 10: Vabysmo: Disease criteria chosen impact patient allocation
Vabysmo: Disease criteria chosen impact patient allocation Vabysmo nAMD trials use disease criteria reflective of clinical practice1 Different ≥Q12W disease criteria as applied to TENAYA/LUCERNE patients Stringent criteria** Share of patients on ≥Q12W dosing Treatment change if ANY criteria are met
Slide 11: R&D focus area Alzheimer's disease
R&D focus area Alzheimer’s disease Clinical results for gantenerumab and blood-based biomarkers to be presented at CTAD Pharmaceuticals gantenerumab • Nearly two decades of scientific investigation with Diagnostics >2,600 patient years on treatment • GRADUATE I/II: Patients with early AD (FDA BTD) B
Slide 12: Elecsys Amyloid Plasma Panel clinical results
Elecsys® Amyloid Plasma Panel clinical results Addressing the unmet need of early detection of Alzheimer’s disease pathology 1 2 3 Triage Confirmation Therapy Patients undergoing initial evaluation Patients referred for amyloid Patients identified for future for non-specific cognitive decline1 confi
Slide 13: Tiragolumab development program on-going
Tiragolumab development program on-going Early data (SKYSCRAPER-01) show encouraging efficiency in 1L PDL1+ NSCLC Anti-TIGIT mAb Tiragolumab development program • Fully human IgG1/kappa Ab with intact Fc • SKYSCRAPER-01 did not meet co-primary PFS endpoint, co-primary OS endpoint was immature at fir
Slide 14: Moving into early disease in oncology
Moving into early disease in oncology Early diagnosis and treatment increases the chance for cure Phase III adjuvant trial program 1 National Cancer Institute, SEER database, literature review; TNBC=triple negative breast cancer; HR=hormone receptor; BC=breast cancer; NSCLC=non small cell lung cance
Slide 15: MS franchise: Subcutaneous dosing and higher dose Ocrevus
MS franchise: Subcutaneous dosing and higher dose Ocrevus Q6M SC dosing readout expected in 2023 Q6M SC Ocrevus cuts administration time to 10 min Ocrevus higher dose vs 600 mg in RMS and PPMS Administration and observation schedule Total time Double-blind treatment (min. of ≥120 weeks) Ocrevuzmab h
Slide 16: Lunsumio/glofitamab
Lunsumio/glofitamab Potential to be first in-class and best-in-class in FL and DLBCL Filing 2022 Approved (EU) • Lunsumio approved in EU in 3L+ FL; filed with FDA with 3L+ approval expected this year1 glofitamab Lunsumio Monotherapy • Glofitamab positive pivotal data in 3L+ DLBCL; submitted to 3L+ D
Slide 17: DMD: Delandistrogene moxeparvovec (SRP-9001)
DMD: Delandistrogene moxeparvovec (SRP-9001) Encouraging data from ongoing Ph I studies Delandistrogene moxeparvovec Ph Ib ENDEAVOR (Study 103) Ph I (Study 101) Functional LSM change NSAA total score over 4 years in results: NSAA from baseline treated patients vs. EC (unadjusted) mean) • Targeted de
Slide 18: Stroke: Tenecteplase in acute ischemic stroke
Stroke: Tenecteplase in acute ischemic stroke Ph III data (TIMELESS) expected in 2023 Tenecteplase TIMELESS study Advanced Imaging - Enables patient Trial design selection Tenecteplase Stroke core (damaged tissue) Tissue at risk CT perfusion images show salvageable brain tissue exists for some patie
Slide 19: YTD Performance update, pipelines, innovation, outlook
YTD Performance update Pharma pipeline Diagnostics pipeline Drive for innovation Outlook
Slide 20: Molecular Lab installed base
Molecular Lab installed base We more than doubled our footprint in the market Installed base for cobas® 6800/8800 +138% ~1,900 ~1,770 ~1,200 ~800 2018 2019 2020 2021 Q1 2022 20
Slide 21: cobas molecular menu expansion driving growth
cobas® 5800/6800/8800 molecular menu expansion driving growth Further growing the installed base in 2022 Donor Screening Blood Borne Disease Sexual Health Transplant Respiratory Antimicrobial Stewardship MPX HIV-1 HPV CMV Flu A/B & RSV (OMNI) MTB-RIF/INH WNV HBV CT/NG EBV MTB C.diff DPX HCV TV/MG BK
Slide 22: New innovations driving market access
New innovations driving market access Mass Spectrometry Emerging Market Analyzer First fully integrated mass spectrometry Routing testing in remote areas ● Integration of mass spec into the Core Lab ● Designed for the specific needs of ● Sample in - result out emerging markets ● Increase patient acc
Slide 23: YTD Performance update, pipelines, innovation, outlook
YTD Performance update Pharma pipeline Diagnostics pipeline Drive for innovation Outlook
Slide 24: Financial impact: Rejuvenating the portfolio and securing the future
Financial impact: Rejuvenating the portfolio and securing the future FY 2021 vs. FY 2017: Pharma Division operational performance FY 2021 FY CHF2021 growth CER growth CHFm abs. CHF CHFmvs abs. FY 2017 CHF vs FY 2017 Sales 45.041 Sales +3.821 -12.8bn 45.045 +5.174 9% -10.9bn 19% thereof AHR 8.315 the
Slide 25: Roche's innovation engines enable high R&D depth and breadth
Roche’s innovation engines enable high R&D depth and breadth Preserving diverse research cultures pRed: Early stage Pharma R&D business unit, Pharma Product Development: Business translating science into medicines pRed unit for late stage Pharma development Product gRed: Early stage Pharma R&D busin
Slide 26: New platform technologies with cyclic peptides and CAR-Ts added
New platform technologies with cyclic peptides and CAR-Ts added *List of pipeline molecules where targets and MOA have been disclosed = Oncology pipeline = Neuroscience and I2O pipeline 26
Slide 27: Partnering and M&A to accelerate pipeline and drive PHC
Partnering and M&A to accelerate pipeline and drive PHC Development stage at time of deal/partnership start Early stage assets Late stage assets Digital & PHC (HBV) (molecular information) (T-cell therapies) (NLRP3 inhibitors) (SRP-9001) (electronic health (SLC (SHP2 inhibitor) (Evrysdi) records) tr
Slide 28: YTD Performance update, pipelines, innovation, outlook
YTD Performance update Pharma pipeline Diagnostics pipeline Drive for innovation Outlook
Slide 29: Consensus outlook 2021-25
Consensus outlook 2021-25 Continued growth driven by already established medicines Biosimilar gap (21-25)* Consensus sales growth (21-25)* Post-HY 2022 consensus survey Ronapreve 1.6 bn Tecentriq 2.7 bn Ocrevus 2.4 bn Lucentis 1.4 bn Gap Hemlibra 2.4 bn Additional up-side by NMEs not Xolair 1.9 bn 7
Slide 30: NME submissions and their additional indications
NME submissions and their additional indications Projects in phase II and III glofitamab + chemo autogene cevumeran bepranemab RG6026 1L ctDNA+ high risk RG6180 RG6416 1L melanoma Alzheimer's New Molecular Entity (NME) Metabolism DLBCL Additional Indication (AI) Neuroscience tiragolumab + T zinpentr
Slide 31: AI submissions for existing products
AI submissions for existing products Projects in phase II and III New Molecular Entity (NME) Metabolism Additional Indication (AI) Neuroscience Oncology / Hematology Ophthalmology Immunology Other Phesgo OBI RG6264 Infectious Diseases HER2+ BC Gavreto Kadcyla + Tecentriq RG6396 RG3502 Tumor agnostic
Slide 32: Doing now what patients need next
Doing now what patients need next